Cell Therapy Product DS Release Specific Testing

Overview Methods Regulatory Customization Contact Us FAQ

Overview

Cell therapy product DS release testing is a core quality attribute service for immune cell therapy products such as CAR T, TCR T, and NK cells. It systematically characterizes cell viability, immunophenotype, replication competent lentivirus/retrovirus (RCL/RCR), and cytotoxic killing activity in drug substance and final product. Methods align with FDA and EMA requirements for live cell drugs.

Cell therapy products are "live" drugs fundamentally different from traditional biologics – their quality attributes cannot be confirmed solely by final product testing but require dynamic monitoring throughout manufacturing. Creative Biogene provides one stop services from DS release testing to IND/BLA submission data packages.

In addition to in vitro release testing, in vivo quality control is critical for CAR T products to ensure safety and efficacy in the clinical setting. We offer in vivo CAR T monitoring services covering expansion kinetics, persistence, phenotype changes, tumor burden, and cytokine related toxicity.

Technical Principles

At a glance – Cell therapy DS release test panel

Test	Method(s)	Typical Information Provided
Cell viability	Flow cytometry (PI/7 AAD), Trypan blue	% live cells (recommended ≥70 80%)
Immunophenotyping	Multi color flow cytometry	T cell lineage, CAR expression, memory subsets, exhaustion markers, purity
RCL/RCR detection	Co culture + qPCR (gold standard) or validated rapid qPCR	Pass/fail – must be free of RCL/RCR
Cytotoxicity potency	Flow cytometry killing assay, LDH release, IFN-γ release	Specific killing % at defined E:T ratios

In Vivo CAR T Quality Control

Beyond release testing, in vivo assessment is essential for CAR T products to confirm functional activity and safety in a physiological context. Key parameters include:

Expansion and persistence – Quantify CAR T cell expansion (peak, area under curve) and persistence over time via flow cytometry or qPCR from peripheral blood or tissues.
Phenotypic changes – Monitor memory subset skewing (naïve, central memory, effector memory) and exhaustion marker upregulation (PD-1, LAG-3, TIM-3) post infusion.
Tumor burden reduction – Measure target cell clearance using bioluminescence imaging (e.g., luciferase expressing tumor cells) or flow cytometry.
Cytokine and toxicity monitoring – Assess CRS related cytokines (IL-6, IFN-γ, TNF-α) and neurotoxicity markers (e.g., IL-15, GM-CSF) to manage safety.

These in vivo data support product potency, dose selection, and clinical trial safety monitoring.

Cell Viability Testing

Cell viability is the percentage of live cells – a fundamental release parameter for live cell drugs. Low viability reduces effective dose and releases DAMPs, triggering unintended immune responses.

Flow cytometry (PI / 7 AAD): Membrane impermeable DNA dyes label dead cells. Live cells exclude dye. High throughput, precise, and allows simultaneous immunophenotyping. Recommended for release testing.
Trypan blue staining: Dead cells take up the dye and appear blue. Low cost, simple, suitable for rapid screening during process development.

Immunophenotyping

Multi color flow cytometry is the core identity test for cell therapy products, confirming lineage, CAR expression, memory subsets, exhaustion status, and purity.

Test Category	Markers	Method	Reference Acceptance Criteria
T cell lineage	CD3+, CD4+, CD8+ percentage	Multi color flow cytometry	Product and process specific
CAR expression	CAR positivity (anti idiotype antibody or protein L)	Multi color flow cytometry	Product and process specific
Memory subsets	CCR7, CD45RA, CD45RO (Naïve/CM/EM/EMRA)	Multi color flow cytometry	Product specific
Exhaustion markers	PD-1, LAG-3, TIM-3	Multi color flow cytometry	Monitor batch consistency
Transduction efficiency	CAR+ cells as % of total T cells	Multi color flow cytometry	Process specific
Purity	CD3+ cells as % of total viable cells	Multi color flow cytometry	≥80–90% (industry practice)

Cytotoxicity Potency Assay

Cytotoxicity is the core functional potency indicator for CAR T/TCR T/NK products. The FDA 2025 draft guidance Potency Assurance for Cellular and Gene Therapy Products requires potency assays to align with the product's mechanism of action and be based on CQAs.

Flow cytometry cytotoxicity assay: Target cells labeled with CFSE/CellTrace Violet are co cultured with effector cells at various E:T ratios. Viability dye (PI/7 AAD) quantifies dead target cells. Specific killing % is calculated.
LDH release assay: LDH released from damaged cells converts tetrazolium salt to a colored product (absorbance at 490 nm). A viable alternative to ⁵¹Cr release.
IFN-γ release assay: CAR T cells co cultured with antigen expressing tumor cells; secreted IFN-γ quantified by ELISA or flow cytometry as a surrogate activation marker.

RCL/RCR Detection

Replication competent lentivirus/retrovirus (RCL/RCR) is a critical safety impurity. Regulators require products to be free of RCL/RCR. The gold standard is co culture with permissive cells followed by qPCR detection. Validated rapid qPCR methods may be used for release after comparability studies.

Regulatory Basis

Document	Key Requirement
FDA CGT Guidance (2020)	CMC information for IND; release testing requirements for cell therapy products.
FDA Draft Guidance (2025)	Potency Assurance for CGT Products – align potency assays with MOA; emphasizes CQAs, GMP, and risk assessment.
ICH Q5A(R2)	Framework for RCL/RCR detection.
USP <63>	Mycoplasma testing – FDA recommends per USP <63>.
USP <71>	Sterility testing – FDA recommends per USP <71>.
USP <1046>	Cell and Gene Therapy Products – viability: FDA recommends >70%, EMA >80%.

Customization Capabilities

CAR construct specific immunophenotyping panels: Custom CAR detection flow cytometry panels based on the client's CAR construct (anti idiotype antibody / protein L / target Fc fusion protein).
Memory subset analysis: Multi parameter panels (CCR7, CD45RA, CD45RO, CD95, etc.) for fine Naïve/CM/EM/EMRA subsetting.
Cytotoxicity method development and validation: Assist clients in developing flow cytometry cytotoxicity, LDH release, or IFN-γ release assays with full validation.
RCL rapid method validation and comparability studies: Validate qPCR rapid methods against FDA recommended co culture methods, generating comparability reports to support rapid release submissions.
Full lifecycle testing for cell therapy products: Testing strategy design from starting material (leukapheresis) through intermediates to final product.
CAR T cell product stability studies: Multi timepoint stability monitoring for cell viability, immunophenotype, and cytotoxicity to support shelf life determination.
In vivo CAR T monitoring: Custom study design for expansion, persistence, phenotyping, tumor burden, and cytokine toxicity assessment – supporting IND enabling pharmacology/toxicology studies.

Contact Us

For a customized DS release testing strategy, method validation, or IND/BLA submission support for your cell therapy product, contact Creative Biogene's technical team.

FAQ

Q1: Are all four tests mandatory for cell therapy product DS release?

A: Yes. Cell viability, immunophenotype, RCL/RCR detection, and cytotoxicity are core quality attributes. RCL/RCR is a safety pass/fail criterion – products must be free of RCR/RCL. The 2025 FDA draft Potency Guidance further emphasizes alignment of potency assays (cytotoxicity) with MOA.

Q2: How to choose between flow cytometry and trypan blue for cell viability testing?

A: Flow cytometry is recommended for release testing – high throughput, high precision, and simultaneous immunophenotyping. Trypan blue is low-cost and simple, suitable for rapid screening during process development. Creative Biogene's recommendation: flow cytometry (PI/7 AAD) for release testing; trypan blue for rapid screening.

Q3: What in vivo CAR T quality control parameters are needed for IND submission?

A: For IND, regulators expect data on CAR T cell expansion (peak and persistence), phenotypic stability (memory/exhaustion markers), tumor burden reduction (efficacy), and safety biomarkers (cytokines, neurotoxicity). Creative Biogene can design customized in vivo studies using NSG or similar models to generate these critical data packages.

* For research use only. Not intended for any clinical use.

Quick Inquiry